GlassScriptPhysician profile
Pierre Hage
NPI 1528175197
$4,854.10
in general payments reported to CMS, 2019-2025
33 companies · $1,121 in 2025
The $1,121 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $264 · 2021: $240 · 2022: $402 · 2023: $848 · 2024: $865 · 2025: $1,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.48 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,005.13 | 2019-2023 | |
| Astellas Pharma US INC | $816.22 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $738.58 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $316.48 | 2022-2025 | |
| Exact Sciences Corporation | $245.79 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Therapeuticsmd, INC. | $200.93 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.60 | 2019-2025 | |
| Hologic Sales and Service, LLC | $142.58 | 2023 | Acessa Provu System |
| Lupin INC. | $127.74 | 2019-2021 | |
| Pfizer INC. | $121.18 | 2022-2025 | |
| Coopersurgical, INC. | $109.92 | 2019-2025 | Paragard T 380a |
| Ge Healthcare | $108.50 | 2025 | |
| Sumitomo Pharma America, INC. | $101.25 | 2023-2025 | Myfembree |
| Allergan, INC. | $92.40 | 2019-2020 | |
| Organon LLC | $73.13 | 2023-2025 | Nuvaring, Nexplanon |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $64.81 | 2024-2025 | Zurzuvae |
| Medtronic, INC. | $59.80 | 2023 | V-Loc 180 |
| Merck Sharp & Dohme LLC | $59.59 | 2019-2021 | |
| Evofem Biosciences, INC. | $38.49 | 2020-2021 | |
| Medicem INC. | $36.55 | 2021-2023 | |
| Sanofi Pasteur INC. | $25.27 | 2024 | |
| Channel Medsystems, INC. | $24.66 | 2024 | |
| Coloplast Corp | $24.53 | 2020 | |
| Shield Therapeutics INC | $24.31 | 2024 | |
| Myovant Sciences INC. | $23.93 | 2022 | |
| Meditrina | $19.66 | 2025 | |
| Mission Pharmacal Company | $17.51 | 2019 | |
| Minerva Surgical, INC | $15.81 | 2025 | |
| Millicent US INC | $15.68 | 2025 | Intrarosa, Femlyv |
| Agile Therapeutics, INC. | $15.28 | 2022 | |
| Duchesnay USA Incorporated | $14.44 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.37 | 2020 | |
| Aspira Women'S Health INC | $13.98 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Hage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.